Connect Biopharma Holdings Ltd. (CNTB), a clinical-stage biopharmaceutical company developing medicines for the treatment of inflammatory diseases, is heading into a catalyst-rich year with a couple of clinical trial readouts ahead.
The company's lead drug candidate is Rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4Ra, a receptor on immune cells that drives inflammation when triggered.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.